Yingjun F. Zhao
Fujian Provincial Key Laboratory Of Neurodegenerative Disease And Aging Research
Xiamen, 361005, China
Xiamen, 361005, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Therapeutic Targeting of Tauopathies: From Druggable Biology to Precision Intervention.
Journal: Pharmacological research
Published: May 05, 2026
MAPT-derived circTau6 induces tau pathogenesis and neurodegeneration by encoding Tau variants.
Journal: Molecular psychiatry
Published: December 15, 2025
Brain-wide microglia replacement using a nonconditioning strategy ameliorates pathology in mouse models of neurological disorders.
Journal: Science translational medicine
Published: April 30, 2025
Efficacy and safety of combined low-dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy.
Journal: Annals of clinical and translational neurology
Published: October 04, 2024
Microglial CD2AP deficiency exerts protection in an Alzheimer's disease model of amyloidosis.
Journal: Molecular neurodegeneration
Published: August 29, 2024
PKCδ serves as a potential biomarker and therapeutic target for microglia-mediated neuroinflammation in Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 28, 2023
Passive immunotherapy for Alzheimer's disease.
Journal: Ageing research reviews
Published: September 21, 2023
Microglial apolipoprotein E particles contribute to neuronal senescence and synaptotoxicity.
Journal: iScience
Published: August 24, 2023
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy.
Journal: Neuron
Published: April 22, 2023
Correction: Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies.
Journal: Journal of neuroinflammation
Published: December 21, 2022
Last Updated: 09/26/2026